Jan Simons, Ph.D.Senior Director, Technology at Gigagen
Dr. Simons is a pioneer in the development and applications of next generation sequencing technologies. Current he leads development of custom technologies for discovery and functional validation of antibody therapeutics at Gigagen. Prior to his current position he held leadership positions at Quantapore, Genapsys, Ion Torrent, and 454 Life Sciences, where he led development and commercialization of next-generation sequencing platforms, including single molecule sequencing and spearheaded pioneering sequencing applications in collaboration with thought-leaders in the fields of oncology, virology and evolutionary genetics. Dr. Simons received a Ph.D. in Medical Science at the Karolinksa Institute in Stockholm, Sweden, and a B.S./M.Sc. in Biochemistry at the University of Helsinki in Finland. He has over thirty peer reviewed publications including seminal publications in Nature and Science. He also has multiple granted or pending patent applications.